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Abstract
Background: Cardiovascular disease (CVD) incidence, complications and burden differ markedly between women and men.
Although there is variation in the distribution of lifestyle factors between the genders, they do not fully explain the
differences in CVD incidence and suggest the existence of gender-specific genetic risk factors. We aimed to estimate
whether the genetic risk profiles of coronary heart disease (CHD), ischemic stroke and the composite end-point of CVD differ
between the genders.
Methodology/Principal Findings: We studied in two Finnish population cohorts, using the case-cohort design the
association between common variation in 46 candidate genes and CHD, ischemic stroke, CVD, and CVD-related quantitative
risk factors. We analyzed men and women jointly and also conducted genotype-gender interaction analysis. Several allelic
variants conferred disease risk for men and women jointly, including rs1801020 in coagulation factor XII (HR=1.31 (1.08–
1.60) for CVD, uncorrected p=0.006 multiplicative model). Variant rs11673407 in the fucosyltransferase 3 gene was strongly
associated with waist/hip ratio (uncorrected p=0.00005) in joint analysis. In interaction analysis we found statistical
evidence of variant-gender interaction conferring risk of CHD and CVD: rs3742264 in the carboxypeptidase B2 gene,
p(interaction)=0.009 for CHD, and rs2774279 in the upstream stimulatory factor 1 gene, p(interaction)=0.007 for CHD and
CVD, showed strong association in women but not in men, while rs2069840 in interleukin 6 gene, p(interaction)=0.004 for
CVD, showed strong association in men but not in women (uncorrected p-values). Also, two variants in the selenoprotein S
gene conferred risk for ischemic stroke in women, p(interaction)=0.003 and 0.007. Importantly, we identified a larger
number of gender-specific effects for women than for men.
Conclusions/Significance: A false discovery rate analysis suggests that we may expect half of the reported findings for
combined gender analysis to be true positives, while at least third of the reported genotype-gender interaction results are
true positives. The asymmetry in positive findings between the genders could imply that genetic risk loci for CVD are more
readily detectable in women, while for men they are more confounded by environmental/lifestyle risk factors. The possible
differences in genetic risk profiles between the genders should be addressed in more detail in genetic studies of CVD, and
more focus on female CVD risk is also warranted in genome-wide association studies.
Citation: Silander K, Alanne M, Kristiansson K, Saarela O, Ripatti S, et al. (2008) Gender Differences in Genetic Risk Profiles for Cardiovascular Disease. PLoS
ONE 3(10): e3615. doi:10.1371/journal.pone.0003615
Editor: A. Cecile J.W. Janssens, Erasmus University Medical Center, Netherlands
Received May 15, 2008; Accepted October 10, 2008; Published October 31, 2008
Copyright:  2008 Silander et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was part of the GenomEUtwin project (www.genomeutwin.org), which was supported by the European Commission under the programme
’Quality of Life and Management of the Living Resources’ of 5th Framework Programme (no. QLG2-CT-2002-01254). This study was supported by the Nordic
Centre of Excellence is Disease Genetics (http://www.ncoedg.org/), the Academy of Finland Centre of Excellence in Complex Disease Genetics (http://www.ktl.fi/
diseasegenetics/MainPage_Eng.htm), and Biocentrum Helsinki (http://www.helsinki.fi/biocentrum/index3.html). The Sigrid Juselius Foundation has supported
Veikko Salomaa and Markus Perola. Jenny and Antti Wihuri Foundation, Aarne Koskelo Foundation, the Finnish Foundation for Cardiovascular Research, the
Research Foundation of Orion Corporation, and the Paulo Foundation are acknowledged for their financial support. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kaisa.silander@ktl.fi
. These authors have contributed equally to this work.
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3615Introduction
According to world statistics for 2006, cardiovascular diseases
(CVD) are responsible for 30% of all deaths globally, and are the
leading cause of death amongst non-communicable diseases.
Cardiovascular diseases are also responsible for 10% of the global
burden of disease [1]. Differences in CVD incidence, complica-
tions and burden exist between men and women. Women are
afflicted with cardiovascular disease at an older age than men, and
many risk variables for coronary heart disease (CHD) and stroke
have different distributions in men and women [2–7]. However,
the differences in lifestyle factors do not fully explain the
differences in CVD incidence between the genders [2]. Genetic
factors also contribute to CHD and stroke susceptibility [8–10]. A
recent large population-based prospective study suggested that
heritability of ischemic stroke was greater in women than men
[11]. Some of the traditional CVD risk factors also have high
heritability [10], some of which show gender differences [12]. A
large scale study of CVD traits in a Sardinian population showed
that for several traits in which heritability estimates differed by
gender, for example weight and hip circumference, the heritability
was larger among women [13]. The evidence for gender
differences in trait heritabilities implies possible gender-gene
interaction in the etiology of these traits [12].
The effect of genetic variables on CHD and ischemic stroke has
been studied for several decades, yet there are only a few consistent
risk factors identified to date [10,12,14–19]. These genetic studies
include few large scale candidate gene studies, as well as numerous
smaller studies, and very recently several genome-wide association
studies. Most of the large scale candidate gene studies published so
far on CHD or stroke have performed combined analyses of both
genders, using gender as a covariate [20–25]. In a Japanese case-
control study of myocardial infarction, men and women were
analyzed separately, and the significant results obtained for men and
women were for different variants [26], indicating different genetic
riskfactors.In a large-scalegeneticassociation study ofthemetabolic
syndrome among CHD patients, McCarthy and colleagues
identified several variants which displayed significant genotype-
genderinteraction [27].Inrecentgenome-wide association studies of
CHD [14–17,19] and ischemic stroke [28], the association results
were reported for the combined study sample of both genders.
We estimated the effect of genetic variation on CHD, ischemic
stroke and the composite end-point of CVD in two prospectively
followed population cohorts. Our study had a case-cohort design
on the FINRISK-92 and -97 cohorts participating in the
MORGAM Project [29]. We selected 46 genes for study as
putatively involved in cardiovascular pathobiology, based on their
function, previous association with cardiovascular disease, and/or
relevant phenotype in animal models. These genes represent a
selected array of pathways, including lipid and energy metabolism,
inflammation, coagulation, and thrombosis. We assessed the risk
associated with common variation in each gene and CHD,
ischemic stroke, and CVD while the cohort setting allowed us to
control for classic CVD risk factors. We also assessed whether the
variants affect relevant quantitative traits that are related to CVD
risk: lipid and C-reactive protein (CRP) levels, blood pressure,
body mass index (BMI), and waist/hip ratio (WHR). Our previous
analysis of candidate genes like upstream stimulatory factor 1
(USF1) and Selenoprotein S (SEPS1, SELS, or SELENOS) mainly
showed genetic effects in women [30,31]. In this study, we
therefore proceeded with a formal genotype-gender interaction
analysis for all variants, and show that for several of the associated
variants, there is evidence for statistical interaction between gender
and genotype.
Materials and Methods
FINRISK cohort description
FINRISK surveys are carried out every 5 years to assess the
prevalence and risk factors of CVD in Finland [32]. Baseline
information on all randomly sampled individuals includes
anthropometric measurements, serum lipids, blood pressure and
questionnaire data on CVD risk factors. Information on fatal and
non-fatal coronary and stroke events and all-cause mortality
during the follow-up period is obtained from national registers. We
utilized the FINRISK-92 cohort (n=5999) and FINRISK-97
cohort (n=8141), which have been followed up for 10 and 7 years,
respectively. On these large cohorts, we conducted a case-cohort
study, as previously described in detail [29,31,33–35]. The cohorts
constituted respondents to surveys of independent random samples
of the same geographically defined population. The resulting few
overlaps were identified on the basis of personal ID codes, unique
to every resident of Finland, and removed from the FINRISK-97
case-cohort set to ensure there was no overlap between the sets
used for the analyses.
We initially studied the FINRISK-92 case-cohort set, which
consisted of a total of 190 incident CHD cases, 66 incident
ischemic stroke cases, 219 individuals with a history of either CHD
or stroke event, 276 individuals who died during the follow-up,
and a random sample (sub-cohort) of 398 individuals from the
cohort. We also analyzed a second case-cohort set selected from
the FINRISK-97 cohort, for genes associated with risk for CHD,
ischemic stroke, the composite end-point of CVD or all-cause
mortality, or strongly associated with quantitative traits in the
FINRISK-92 case-cohort set. This sample included 210 incident
CHD cases, 84 incident stroke cases, 436 individuals with a history
of either CHD or stroke event, 352 individuals who died during
the follow-up, and 407 sub-cohort individuals. The sub-cohort was
a sex- and geographic-region stratified random sample, drawn
from each of the original cohorts with unequal sampling
probabilities so that the age distribution was similar to the cases.
The selection procedure for the cases and the sub-cohort, and the
exact diagnostic criteria used for CHD and ischemic stroke have
been described in detail previously [29,31,33–35]. The case-cohort
sets included in this study are described in Tables 1 and 2. All
participants gave informed consent. In 1992 it was not yet
customary to ask for a written consent, thus only oral informed
consent exists for that survey. In 1997 a written informed consent
was obtained from all survey participants. The law about the
National Public Health Institute of Finland gives the Institute a
possibility to also use the samples from the 1992 survey for public
health research. The study was approved by the Ethics Committee
of the National Public Health Institute of Finland and conformed
to the principles expressed in the Declaration of Helsinki.
Quality control of DNA samples
We implemented several quality control measures to minimize
errors associated with DNA sample handling and DNA quality,
and excluded a total of 19 samples chosen as cases or in the sub-
cohort. These 19 individuals are not included in Table 1. A
gender-specific PCR test identified a total of 9 samples (0.4%) that
had a different gender than expected, and they were subsequently
excluded from the study. We also verified that the DNA sample
was of good quality by testing five highly polymorphic microsat-
ellite markers for each sample. In these analyses, one sample was
found to be contaminated and was excluded. DNA samples with
low DNA yield (,7.5 mg of genomic DNA) as measured by
fluorescent label PicoGreen (Invitrogen, Carlsbad, CA, USA) were
subjected to whole genome amplification before genotyping,
Genetic Risk Profiles
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samples were excluded due to biased whole genome amplification,
and a further 4 samples were excluded due to extremely low
quantities of DNA which was insufficient for whole genome
amplification.
Variant selection
For each gene, we aimed to genotype a set of variants that
would capture the common variation present in the gene, as well
as variants that have been previously associated with CVD or
related traits. For the majority of the genes, haplotype-tagging
single nucleotide polymorphism (SNP) variants were selected from
the SeattleSNPs database (http://pga.gs.washington.edu/). The
SeattleSNPs project has resequenced the genes using 24 Centre
d’Etude du Polymorphisme Humain DNA samples, and tag SNPs
have been selected using LDSelect, an algorithm that is based on
the linkage disequilibrium (LD) statistic r
2 [37]. We selected tag
SNPs from each multi-SNP bin with a frequency .10%. For genes
that were not included in the SeattleSNPs sequencing project, we
selected variants from public databases (Celera, dbSNP), at
approximately 5 kb distance from one another, giving priority to
variants with known frequency information. Once HapMap phase
I data were available, we selected additional variants to better
capture the common variation in these genes. More detailed
information about gene cladistics, sequence and haplotype
structure information was available for apolipoprotein E (APOE),
lactase (LCT), and lipin 1 (LPIN1)-genes, and here variant selection
was based on previously published sequencing and haplotype
analysis [38–41]. A full list of the variants selected for study and
successfully genotyped (see below) is provided in Table S1.
Variant genotyping
Variant genotyping was done using several genotyping plat-
forms (Table S1). Approximately 5.5% of the genotypes were
created with an in-house developed method of allele-specific
primer extension on microarrays, as previously described [36].
Approximately 93.0% of the genotypes were produced with the
MassARRAY System (Sequenom, San Diego, CA, USA), either
with the homogeneous Mass Extension (hME) reaction or iPLEX
reaction, using the protocols recommended by the manufacturer
with these modifications: hME reactions were carried out with 5–
7.5 ng of DNA and for the majority of the variants, the hME
extension reaction was run using TERMIPol DNA polymerase
(Solis Biodyne OU ¨, Tartu, Estonia) [42] instead of Thermo-
Sequenase (GE Healthcare Life Sciences, Chalfont St. Giles, UK).
The two APOE variants that define the epsilon genotypes
(rs429358 and rs7412) were genotyped on the MassARRAY with
a modified protocol as previously described [43] (full protocol
available from authors upon request). Three of the variants were
genotyped with other platforms: rs4340 was genotyped by a PCR
assay followed by separation on 2% agarose gel with ethidium
bromide staining and rs28665122 and rs3216183 were genotyped
with TaqMan (Applied Biosystems, Foster City, CA) [30,44]. For
100 samples where inadequate amount of genomic DNA was
available, the DNA was amplified with GenomiPhi DNA
amplification kit (GE Healthcare Life Sciences), as previously
described [36].
Before genotyping the FINRISK case-cohort samples we
genotyped all variants on 60 anonymous Finnish trio samples
and 180 unrelated control samples. The FINRISK samples were
genotyped in plates containing 2% negative control samples, 2%
known duplicate samples, and 5% blind duplicate samples to allow
assessment of genotyping quality. The disease status of each
individual genotyped was unknown to the genotyping laboratory
and samples from cases and sub-cohort individuals were
distributed on the plates independently of the disease status. All
genotypes were manually reviewed for various quality control
aspects as previously described [36,42,45]. The genotyping success
rate for each variant included in the analysis was .90%, with an
average genotyping success of 95.3%. Among the 27,522
successful blind duplicate genotypic pairs, we detected 37
genotypic inconsistencies (99.87% concordance between geno-
types). All variants included in analyses were in Hardy-Weinberg
equilibrium (HWE) in the sub-cohort sample (p.0.01). A single
Mendelian error was identified for 3 variants among the 60 trio
samples (rs1926446, rs3212478, and rs1081106). However, since
the genotypes for these variants were in HWE and no errors were
detected among known and blind duplicates, these variants were
included in the analysis.
Statistical analysis
Genotype frequencies in sub-cohort individuals were tested for
deviation from HWE using Pearson’s chi-square test statistics with
1 degree of freedom for bi-allelic variants and 3 for three-allelic
Table 1. Number of individuals in each of the case status categories in the FINRISK-92 and FINRISK-97 case-cohort study.
FINRISK-92 FINRISK-97
women men women men
TOTAL GENOTYPED 347 635 331 887
Sub-cohort
a 114 284 87 320
Incident coronary cases
b 52 138 51 159
Incident stroke cases
b 32 34 21 63
Incident cardiovascular disease cases
b 84 165 70 208
Death during follow up 91 185 91 261
Prevalent cardiovascular disease
c 62 157 117 319
Incident CVD cases/baseline CVD cases in sub-cohort 7/3 37/29 10/7 30/59
Incident CVD cases/baseline CVD cases among deaths 11/7 48/47 25/14 60/79
aRandom sample of the cohort, which included also some cases.
bThese were incident during follow-up.
cCardiovascular disease at baseline.
doi:10.1371/journal.pone.0003615.t001
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one of the genotype groups had less than 5 individuals, HWE was
calculated using an exact test. Allele segregation within trio
families was analyzed with the PedCheck program [46]. Pair-wise
LD between the variants in each gene, haplotype frequencies, and
haplotype tags were assessed with Haploview software version 3.32
[47]. For variants in high LD with each other (r2.0.95), only one
of the results is shown.
Time-to-event analysis was used to assess whether any of the
tested allelic variants have effect on the incidence of CHD,
ischemic stroke, or CVD. The effects under recessive, dominant
and multiplicative models of individual variants were tested using
the proportional hazards regression model where the case-cohort
design was taken into account by applying a modification of the
Prentice weighting [48], with the non-case sub-cohort members
and sub-cohort cases before events weighted with the inverses of
their individual inclusion probabilities to account for the over-
sampling of cases[34]. Estimation of model parameters and
standard errors was carried out in R statistical environment, using
the coxph function of the package survival and its robust variance
estimator. We adjusted for classic CVD risk factors: smoking, high
density lipoprotein-cholesterol (HDL-C), non-HDL-cholesterol,
history of diabetes, BMI, and hypertension, as well as geographic
region (western Finland, northern Finland, and eastern Finland),
and cohort (and gender for combined analysis in women and
men). Age was used in the models as the time scale. We fitted two
types of models. In the first model, men and women from both
cohorts were analyzed jointly, as described above. In the second
model, we carried out a test for genotype-gender interaction,
defined as a departure from multiplicative, dominant or recessive
model, using similar regression models and testing the null
hypothesis of equality of genotype effect parameters between
men and women. We report results in which the variant genotype
specific p-value is #0.01 for either men or women. We verified
that these results do not stem from a single cohort by testing the
null hypothesis of equality of genotype effect parameters between
FINRISK-92 and FINRISK-97 cohorts, using a similar regression
model. For variants that conferred a risk at p,0.05 for CHD, we
also studied the association in prevalent CHD cases (documented or
self-reported myocardial infarction or unstable angina pectoris at
baseline), using healthy sub-cohort subjects as controls. The analysis
ofprevalentcaseswascarriedoutusinglogisticregression,againwith
inverse sampling probability weighting, and using age, cohort and
geographic region, and gender as covariates for the combined
analysis of men and women. Analysis of haplotype effects was done
for two variants of the F12 gene that were not in very high LD with
each other and were both associated at p,0.01 with CHD and
CVD.Haplotypeanalysiswasdone withanadditivemodel,inwhich
the common haplotype (containing the ‘non-risk’ alleles) was used as
reference, and modeling an additive effect for the other haplotypes,
in a weighted Cox proportional hazards model, applying the same
weighting scheme and covariates that were used for single variant
analysis, and using the PHREG procedure implemented in SAS
version 9.1.3 SP4. Haplotype uncertainty was taken into account
using multiple imputations, where a sample of haplotypes was
obtained using Phase 2.1.1 software and the analysis was repeated
for each sampled haplotype pair.
Additionally, we tested whether allelic variants were associated
with quantitative traits measured at baseline in sub-cohort
individuals without a history of CVD. The lipid variables studied
were: serum total cholesterol, HDL-C, triglycerides, and low
density lipoprotein-cholesterol (LDL-C). LDL-C was calculated
from measured values of total cholesterol, HDL-C and triglycer-
ides using Friedewald’s formula and excluding individuals with
triglyceride value .4.0 mmol/l. Additional variables studied were
mean blood pressure (average of systolic and diastolic blood
pressure, each value based on two subsequent measurements),
high sensitivity CRP, BMI, and WHR. Association of the variants
with baseline measurements was tested using standard linear
regression, employing additive, dominant, and recessive models,
while adjusting for cohort, age, geographic region, and gender.
Tests for genotype-gender interaction, defined as a departure from
additive, dominant or recessive model, were carried out using
similar regression models and testing the null hypothesis of
equality of genotype effect parameters between men and women.
Individuals using lipid lowering medication were excluded from
the analyses of lipid variables, and individuals using drugs for
hypertension were excluded from the analysis of blood pressure.
We used logarithmic transformation for CRP and triglycerides.
We verified that the results reported do not stem from a single
cohort by testing the null hypothesis of equality of genotype effect
parameters between FINRISK-92 and FINRISK-97 cohorts,
using a similar regression model.
For genes in which two or more variants (not in perfect LD) were
associated at p,0.01 with a given quantitative trait, we also
performed haplotype analysis to discern which allelic haplotype
might be contributing to variation in the trait. Haplotype tagging
variants were identified with the Haploview software version 3.32
using default settings. Analyses with the haplotype-tagging variants
were performed with the haplo.stats package of the R statistical
software [49], using the function haplo.glm with an additive model,
and adjusting for age, cohort, geographic region and gender. The
haplo.glm function estimates haplotype frequencies with the EM
algorithm and calculates for each haplotype linear regression
coefficient and p-value, comparing each haplotype to a base
haplotype, defined as the most common haplotype. Rare haplotypes
(frequency ,0.05) were combined with the base haplotype for this
analysis. The global p-value for haplotype effect coefficients was
calculated for the null hypothesis of no effect for any haplotype.
For the initial analyses of the FINRISK-92 case-cohort alone,
time-to-event analyses and quantitative trait analyses were done as
previously described [30,31,33], analyzing women and men both
separately and together. We did not perform formal gender-
genotype interaction analysis or haplotype analysis at this stage.
In reporting the findings, we used a cut-off value of 0.01 for the p-
values and reported uncorrected p-values. The cut-off value of 0.01
corresponds to posterior odds 6:1 of a finding being a true signal
when we expect to see two signals among the 27 independent genes
and our power is 70% (see The Wellcome Trust Case-control
Consortium’s 2007 paper for details) [19]. The effect of multiple
testing was addressed with standard Q-Q-plots for the individual test
statistics and with false discovery rate (FDR) analysis [50,51]. The
tail-area FDR statistic for a group of tests can be interpreted as the
expected proportion of null results given the observed test statistics.
TheanalysiswascarriedoutusingtheRpackage‘‘fdrtool’’[52].The
method used for power simulations is described in more detail
elsewhere [34]. The reported results are for both cohorts combined,
for tests of the nullhypothesis of no genotype effects (or no genotype-
gender interaction) at 1% significance level. While simulating
genotype-gender interaction we assumed no genotype effects for
men while varying the effect for women.
Results
Study outline
The case-cohort sets from the FINRISK-92 (10 year follow up,
57,858 person-years) and FINRISK-97 (7 year follow up, 54,577
person-years) population cohorts [31] are presented in Tables 1
Genetic Risk Profiles
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genotyped for each gene are presented in Table 3, and detailed
information on all variants is presented in Table S1. In addition to
known CVD candidate genes, we explored the effect of variation
in the LCT gene on CVD risk and CVD related quantitative traits,
because of previous findings of reduced triglyceride and cholesterol
values in individuals with lactose malabsorption [53,54]. We also
studied one novel gene, apolipoprotein B mRNA editing enzyme
(APOBEC2), which is located directly under a linkage peak (lod
score of 4.44) for total cholesterol in our linkage study of 5775
individuals from twin families from the GenomEUtwin (www.
genomeutwin.org). Individual results of the analysis for several of
the genes have already been published: USF1, thrombomodulin
(THBD), SEPS1, coagulation factor V (F5), protein C (PROC), and
intercellular adhesion molecule 1 (ICAM1) [30,31,33,44]. We
include these genes here to provide a more complete picture of the
observed difference in genetic susceptibility between men and
women, and because formal genotype-gender interaction analysis
was not reported for any of the genes in our previous publications.
The study outline is presented in Figure 1. Initially, we studied
the 46 genes in the FINRISK-92 case-cohort set. We selected for
further study in the FINRISK-97 sample 27 genes in which one or
more variants showed an association with CHD, ischemic stroke,
CVD, total mortality, or any of the quantitative traits in the
FINRISK-92 cohort, either in women or men separately, or in
combined analyses. The selection criterion was 60% FDR. A total
of 172 variants were thus typed also in the FINRISK-97 case-
cohort samples, as indicated in Table 3 and Table S1, and
analyzed using the combined FINRISK-92 and FINRISK-97
case-cohort sets. Power simulations are presented in Figures S1
and S2. For time-to-event analysis (Figure S1), the combination of
the two cohorts has a 88% power to detect a dominant gene main
effect on CVD risk of 1.8 in men at p=0.01, a 39% power to
detect a similar effect in women, and 96% power to detect this
effect size when analyzing women and men together, given a risk
allele frequency of 0.2 assuming a proportional hazards model. For
a higher allele frequency the power is somewhat higher. For gene-
gender interaction analysis, our study sample has power to detect
only large differences in risk effects at p=0.01, for example 38%
power to detect a difference of HR=1.0 versus HR=1.8 for allele
frequency of 0.4. For quantitative traits (Figure S2), combining
both cohorts provides a power of 75% for detecting a 0.3 standard
deviation difference at allele frequency of 0.2 in men at p=0.01,
while the power is much lower for the smaller study sample of
women. For gene-gender interaction analyses the power is .85%
only for large differences in the effects, for example no effect in
men and a coefficient of 0.6 in women.
Time-to-event analysis results
Analysis of both genders jointly. Time-to-event analysis
was used to assess the association between variants and CHD,
ischemic stroke and the composite end point of CVD. Results with
p#0.01 from combined analysis of both cohorts and both genders
are shown in Table 4. The estimated FDR for the set of all
association tests (including tests for quantitative traits) with p#0.01
is 53%. These analyses identified variants in angiotensin II
receptor type 1 (AGTR1), APOE, carboxypeptidase B2 (CPB2), and
coagulation factor XII (F12) as conferring risk of CHD. The two
variants of the F12 gene also conferred risk of CVD, as did one
variant of fibrinogen alpha chain (FGA) gene. Haplotype analysis
for the two F12 variants, rs4976691 and rs1801020, in which
carriers of the specific ‘risk’ haplotypes (CA, CG, or GA for
rs4976691 and rs1801020, respectively) were compared to
individuals homozygous for the non-risk haplotype GG did not
reveal stronger association with CHD or CVD than analysis of
single variants. For ischemic stroke, only one SEPS1 variant,
rs7178239, was associated at p#0.01 in the combined analysis of
both genders, but only the women contributed to this effect (see
below). The most consistent result was for CHD association with
the F12 variant rs1801020 (men and women combined, p=0.005
for additive model), which also conferred risk at the p,0.05 level
for CHD in both women and men when analyzed separately. The
rest of the variants showed association at p,0.05 level in only one
gender. We tested whether the results were driven by only one of
the cohorts by assessing genotype-cohort interaction, and observed
no interaction at p,0.05, suggesting that the results are similar in
both cohorts. Variant rs440446 of APOE showed association at
p,0.05 also in both cohorts separately, while the rest of the
variants showed association at p,0.05 in one cohort only, though
a similar trend was observed in the other cohort.
Gender-genotype interactions. We performed gender-
genotype interaction analysis to identify variants that showed
different genetic effects in women and men. This test is sensitive to
both effect direction and effect size. The variants that gave
interaction p-value#0.01 and were associated with CHD,
ischemic stroke or the composite end-point of CVD at p#0.01
in either women or men in combined analysis of both cohorts are
presented in Figure 2 and Table S2. The estimated FDR for the
set of all interaction tests with p#0.01 is 70%, but by using the
additional criteria of association p-value#0.01 in at least one of
the genders, the actual FDR is likely to be smaller. The gender-
genotype interaction analysis supports our previous findings for
USF1 and SEPS1 variants in which the disease risk was limited to
women [30,31], providing a gender-genotype interaction p-
values,0.01 for the USF1 variant rs2774279 and for two SEPS1
variants, rs4965814 and rs9874. For the USF1 variant rs2774279,
the results were also at p,0.05 for women in each cohort
separately. Furthermore, for rs2774279 we also found evidence for
association when analyzing prevalent female CHD cases in both
cohorts combined (odds ratio of 1.58, 95% CI 1.04–2.40,
p=0.03). We identified variants in additional genes which
showed gender-genotype interaction: CPB2 and coagulation
factor XIII, A1 polypeptide (F13A1) conferred gender-specific
risk in women for CHD, another variant in CPB2 conferred risk
for CVD, and F5 for ischemic stroke; and for men, interleukin 6
(IL6) for CVD. The data obtained with F5 variant rs970741 is
based on relatively small groups, with only 12 women incident
stroke cases carrying the protective allele, and the result should be
interpreted with caution. Genotype-cohort interaction analysis
showed that none of the gender-specific results emerge from a
strong effect in only one of the cohorts but rather both cohorts
contribute to the result. For purpose of future meta-analyses, we
provide data for all variants analyzed in both cohorts showing
genotype-specific hazard ratios for men and women separately and
number of individuals and person years in each genotype group
(Tables S3a–c).
We tested which of the variants conferring a CHD risk at p
,0.05 were also associated with CHD in the prevalent cases. In
addition to USF1 variant rs2774279, also the T allele of variant
rs2073658 of USF1 conferred risk in both incident and prevalent
female cases (HR=1.62, 95% CI 1.04–2.52, p=0.03 for incident
cases, and odds ratio=1.87, 95% CI 1.26–2.76, p=0.002 for
prevalent cases, additive model, T risk allele). A variant in the
APOBEC2 gene, rs2395754, was associated with CHD in both
prevalent and incident male cases (HR=1.45, 95% CI 1.04–2.02,
p=0.03 for incident cases, and odds ratio=1.43, 95% CI 1.06–
1.94, p=0.02 for prevalent cases, C allele homozygotes compared
to T allele carriers).
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Inflammation & thrombosis Gene symbol Location # variants
studied in both
FR92 and FR97
carboxypeptidase B2 (plasma) CPB2 13q14.12 10 yes
CD14 molecule CD14 5q31.3 3 yes
coagulation factor II (thrombin) F2 11p11.2 3
coagulation factor II (thrombin) receptor F2R 5q13.3 3
coagulation factor V (proaccelerin, labile factor) F5 1q24.2 21 yes
coagulation factor VII (serum prothrombin conversion accelerator) F7 13q34 3
coagulation factor X F10 13q34 3
coagulation factor XII F12 5q35.3 3 yes
coagulation factor XIII, A1 polypeptide F13A1 6p25.1 9 yes
C-reactive protein, pentraxin-related CRP 1q23.2 6 yes
fibrinogen alpha chain FGA 4q32.1 5 yes
fibrinogen beta chain FGB 4q32.1 5 yes
fibrinogen gamma chain FGG 4q32.1 4 yes
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) ITGA2 5q11.2 6
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 17q21.32 3
intercellular adhesion molecule 1 (CD54), human rhinovirus receptor ICAM1 19p13.2 6 yes
interleukin 1, alpha IL1A 2q13 2
interleukin 1, beta IL1B 2q13 4
interleukin 10 IL10 1q32.1 4
interleukin 6 (interferon, beta 2) IL6 7p15.3 6
lectin, mannose-binding, 1 LMAN1 18q21.32 6
lymphotoxin alpha (TNF superfamily, member 1) LTA 6p21.33 4 yes
plasminogen activator, tissue PLAT 8p11.21 4
protein C (inactivator of coagulation factors Va and VIIIa) PROC 2q14.3 6 yes
selectin E (endothelial adhesion molecule 1) SELE 1q24.2 3
selectin L (lymphocyte adhesion molecule 1) SELL 1q24.2 6
selectin P (granule membrane protein 140kDa, antigen CD62) SELP 1q24.2 1
selenoprotein S SEPS1 15q26.3 6 yes
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 SERPINE1 7q22.1 6 yes
thrombomodulin THBD 20p11.21 9 yes
tumor necrosis factor (TNF superfamily, member 2) TNF 6p21.33 2 yes
vascular cell adhesion molecule 1 VCAM1 1p21.2 4
Lipids & energy
apoliprotein A-V APOA5 11q23.3 6 yes
apoliprotein E APOE 19q13.32 7 yes
forkhead box C2 (MFH-1, mesenchyme forkhead 1) FOXC2 16q24.1 4
lactase LCT 2q21.3 5 yes
lipin 1 LPIN1 2p25.1 7 yes
neuropeptide Y NPY 7p15.3 4 yes
thioredoxin interacting protein TXNIP 1q21.1 3
upstream stimulatory factor 1 USF1 1q23.3 6 yes
Others
5,10-methylenetetrahydrofolate reductase (NADPH) MTHFR 1p36.22 3
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 ACE 17q23.3 4 yes
angiotensin II receptor, type 1 AGTR1 3q24 7 yes
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 APOBEC2 6p21.1 6 yes
fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group) FUT3 19p13.3 3 yes
klotho KL 13q13.1 9 yes
doi:10.1371/journal.pone.0003615.t003
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We tested whether any of the 172 variants was associated with
the CVD-related quantitative traits: total cholesterol, HDL-C,
LDL-C, triglycerides, CRP, BMI, WHR and mean blood
pressure, analyzing the sub-cohort individuals without a history
of CVD at baseline examination. The results showing association
in the combined data analyses of both genders at significance level
of p,0.01 are shown in Table 5. The estimated FDR for the set of
all association tests (including tests for time-to-event responses)
with p#0.01 is 53%. We identified 3 variants displaying effect
differences between the cohorts using genotype-cohort interaction
analysis (interaction p-value ,0.05), and they were removed.
APOE variant rs440446, conferring risk for CHD in time-to-event
analysis (Table 4), was associated with triglyceride values, and FGA
variant rs2070018 was associated with mean blood pressure, with
heterozygotes having the highest blood pressure values. None of
the other variants associated with CHD, ischemic stroke, or CVD
at p#0.01 in women and men combined, was associated at
p,0.01 with the quantitative traits tested here. However, we
identified several interesting associations with each of the traits
studied, as discussed below.
The strongest association identified for quantitative traits in the
combined analysis of women and men was for fucosyltransferase 3
(FUT3)v a r i a n trs11673407 and WHR. For men the additive model
gavea p-value=0.00006;forwomen the associationwasweaker,but
inthesamedirection(p=0.07).HaplotypeanalysisforWHR inmen
using the FUT3 variants rs874232, rs778986,a n drs11673407
identified haplotype CAG as the only one associated with WHR,
compared to base haplotype TAA (p=0.00008) (Table S4a),
suggesting that the true causal variant is not one of these 3 variants.
Another strong association was found for a rare synonymous CRP
variant, rs1800947, and CRP levels in men (p=0.0001, recessive
model).
The LCT variants were associated with total cholesterol and
LDL-C in the combined data: The lactase non-persistence
genotype (defined as minor allele homozygotes for variant
rs4988235) was associated with higher cholesterol values. Similarly
to FUT3 variant, the association was stronger for men (for total
cholesterol, p=0.003 and p=0.005 for variants rs4988235 and
rs6719488, respectively, and for LDL-C p=0.002, and p=0.0005
for variants rs4988235 and rs6719488, respectively), and in females
the association was weaker but in the same direction. Haplotype
analysis using the 3 haplotype-tagging variants rs2304371,
rs6719488, and rs4988235 for men implied that haplotype
GGG, tagged by the G allele of variant rs2304371 was the one
associated with both traits, p=0.003 for total cholesterol and
p=0.005 for LDL-C (compared to base haplotype ATA) (Table
S4b). Sub-cohort men homozygotes for the G allele of rs2304371
Figure 1. Study outline.
doi:10.1371/journal.pone.0003615.g001
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to 3.74 for GA genotype (n=109) and 3.55 for AA genotype
(n=243), p=0.014 for the additive model. Variants rs6719488
and rs2304371 are located in the LCT gene itself, while the lactase
non-persistence variant is located at 14 kb distance upstream of
the LCT gene. The LCT locus on chromosome 2q21.3 is known for
being strongly selected during human evolution, with the lactase
persistence allele varying in frequency in different populations and
even between geographic regions [55]. We observed no differences
in allele frequencies of the lactase persistence genotype in the
geographic regions studied here (G allele frequency 0.46 in
Western Finland and 0.44 in Eastern Finland).
Variants that showed different effects on CVD-related quanti-
tative traits in women and men are shown in Table 6, using an
interaction p-value cut off #0.01 and an association cut off
p,0.01 in either women or men in combined analysis of both
cohorts. The estimated FDR for the set of all interaction tests with
p#0.01 is 70%, but the additional criteria of association p-
value,0.01 in at least one of the genders makes the actual FDR
smaller than the upper limit of 70%. As for the disease risk, also
here variants in different genes were associated with the traits in
women and men. In women, variants in the fibrinogen genes (FGA
and FGG) were associated with HDL-C. Interestingly, none of the
genes that are in lipid pathways were associated with lipid
variables in women at p,0.01. For weight-related variables,
variants that showed gender-specific effect were identified only in
women. USF1 variant rs2774279, which was associated with CHD
and CVD risk, was also associated with BMI in women, though
risk allele carriers had lower BMI. Women with the risk allele also
had lower values of CRP. Three variants in ICAM1 gene
associated with WHR in women. Haplotype analysis did not
reveal any ICAM1 haplotypes associated more strongly with the
trait than single alleles. The largest number of gender-genotype
interactions was identified for CRP levels in females.
For men, the APOBEC2 variant rs2395754, which associated
with CHD in both incident and prevalent cases, was also
associated with cholesterol variables. Men carrying the risk allele
had higher levels of LDL-C, p=0.001. In men also a variant in the
serpin peptidase inhibitor, clade E member 1 gene was associated
with mean blood pressure. In addition to these findings, very few
male-specific results at p,0.01 were identified, as shown in
Table 6. The strongest associations with lipids for men were for
variants that also showed the same trend in women, as discussed
above.
Discussion
The hormonal environment as well as tissue specific gene
expression is known to differ significantly between the genders in
vertebrates. For many human diseases, gender-dependent differ-
ences in the progression and extent of disease have been explained
by sex hormones. These hormones may differentially affect gene
expression in somatic tissues, thus leading to the gender specific
susceptibility to disease [56]. Also for cardiovascular disease,
critical determinants of gender differences are sex steroid
hormones and their receptors [57]. They interact with and
activate, together with other proteins, genes that are possibly
involved in CVD pathogenesis in the endothelial and smooth
muscle cells [2,57]. Sex steroid hormones are also expressed in the
liver and regulate lipid levels, mostly through hepatic effects on
lipoprotein metabolism [57].
Although women and men differ in various aspects related to
CHD and ischemic stroke [2–4,6,7], the difference in genetic
effects on disease and its risk factors between women and men
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PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e3615remains largely unexplored territory [12]. Recent genome-wide
association studies also do not address this issue [14–17,19,58]. In
this candidate gene study we explored the genetic risk profiles for
CHD, ischemic stroke and the composite end point of CVD in
men and women, as well as the effect of the specific genetic
variants on CVD-related quantitative risk factors. Our case-cohort
study was based on two prospective cohorts from the relatively
homogeneous Finnish population, the sub-cohort representing a
random subsample of the original cohort. Detailed information on
CVD risk factors recorded before the occurrence of CVD events
allowed us to control for confounding factors, such as smoking,
lipid levels, blood pressure and obesity, while the inclusion of two
separate cohorts allowed for the verification of results. We
identified variants in several genes as conferring disease risk for
both men and women jointly, while other variants showed
evidence for a gender-specific effect. We also identified variants
that were associated with quantitative CVD risk factors in both
men and women combined, and other variants that showed
evidence for gender-genotype interaction. A recent review of
gender differences in genetic effects has suggested three criteria for
appropriately documented gender differences: (1) The genetic
effect is based on the same genetic contrast in both genders; (2)
Different genetic subsets in the 2 genders are not compared; and
(3) Evidence for a nominally statistically significant gender-gene
interaction exists [59]. Our study fulfils all these criteria for the
genetic variants showing different effects in men and women.
However, studies that replicate these results in larger study
samples would be required to confirm or refute the gender-specific
associations presented here. With pooling of information across
the latest genome-wide association studies [14,16,17,19,28], there
is ample opportunity to test for the presence of gender-genotype
interactions behind CHD and ischemic stroke at a genomic level.
In this study, we identified variants in CPB2, F13A1 and LPIN1
as contributing to female-specific risk for CHD and/or CVD, in
Figure 2. Gender-specific association between variants and coronary heart disease, ischemic stroke, and cardiovascular disease.
Results for gender-genotype interaction at p,0.05, and association in either women or men were at p#0.01 (uncorrected p-values). Allele
information: allele 1/allele 2, the minor allele is underlined. Multiplicative model: 11.12.22, dominant model: 11+12 vs 22, recessive model: 11 vs
12+22. Variants showing high pair-wise LD: CPB2 rs3581419 and rs3742264 (r
2=0.827), SEPS1 rs496581 and rs7178239 (r
2.0.7), and SEPS1 rs9874 and
rs7178239 (r
2.0.7). Detailed information is found in Table S2.
doi:10.1371/journal.pone.0003615.g002
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PLoS ONE | www.plosone.org 10 October 2008 | Volume 3 | Issue 10 | e3615Table 5. Results with p,0.01for associations between variants and quantitative traits as measured at baseline examination in sub-
cohort subjects free of CVD at baseline, women and men combined.
Gene Variant rs# Minor/major allele Model
a P
b Measured mean value Number of individuals
hom
(minor) HET
hom
(major)
hom
(minor) HET
hom
(major)
Total cholesterol (mmol/l)
LCT rs4988235
c G/A add 0.002 5.80 5.70 5.48 110 243 159
LCT rs6719488
c G/T add 0.003 5.93 5.71 5.55 57 215 239
LPIN1 rs1050800 T/C dom 0.008 5.68 5.48 5.73 11 150 352
PROC rs5937 A/G dom 0.007 5.51 5.58 5.76 41 208 256
HDL cholesterol (mmol/l)
APOA5 rs619054 A/G add 0.0006 1.42 1.36 1.29 40 170 304
F5 rs7542281 T/C add 0.007 1.25 1.28 1.38 61 226 228
FUT3 rs11673407 G/A dom 0.008 1.38 1.35 1.27 64 248 197
LPIN1 rs2577262 A/G rec 0.009 1.43 1.30 1.29 74 242 197
LDL cholesterol (mmol/l)
APOA5 rs619054 A/G add 0.01 3.23 3.60 3.67 40 163 295
APOE rs7412 T/C dom 0.0003 2.43 3.18 3.64 1 38 445
LCT rs4988235
c G/A add 0.002 3.76 3.63 3.48 106 233 156
LCT rs6719488
c G/T add 0.0008 3.93 3.64 3.52 56 209 229
Triglycerides (mmol/l)
APOA5 rs3135506 C/G dom 0.001 2.53 2.01 1.71 2 85 616
APOA5 rs2072560 T/C dom 0.0004 3.25 2.01 1.67 4 113 567
APOE rs440446 C/G add 0.005 1.65 1.59 1.89 52 281 359
F5 rs2269648
c T/C rec 0.005 1.32 1.82 1.76 44 270 358
THBD rs6082986 G/A rec 0.001 1.44 1.80 1.73 65 313 317
C-reactive protein (mg/l)
APOE rs429358 C/T add 0.002 1.50 2.50 3.75 22 172 413
CRP rs1800947 G/C dom 0.0001 0.28 1.92 3.54 3 74 554
F5 rs9332575 C/T rec 0.003 8.00 2.86 3.14 12 118 496
FGB rs1044291 T/C rec 0.008 7.79 2.39 3.43 28 224 362
Mean blood pressure (mm Hg)
FGA rs2070018 G/A add 0.008 113 117 112 13 139 407
FGG rs1049636 G/A dom 0.003 115 115 112 88 267 203
Body mass index (kg/m
2)
F13A1 rs3024319 C/G rec 0.002 28.7 27.3 27.7 110 310 273
F5 rs9332575 C/T rec 0.008 30.9 27.4 27.7 12 133 554
FUT3 rs11673407 G/A add 0.009 26.6 27.6 28.1 86 331 279
ICAM1 rs3093032 T/C rec 0.005 25.1 27.9 27.7 16 170 498
Waist/hip ratio
CRP rs1130864 A/G add 0.002 0.899 0.915 0.916 88 302 311
F13A1 rs3024319 C/G rec 0.007 0.926 0.911 0.914 110 310 273
F5 rs9332640 G/C rec 0.002 0.895 0.919 0.922 137 365 193
FUT3 rs874232 C/T add 0.003 0.911 0.91 0.922 124 355 217
FUT3 rs11673407 G/A add 2.00E-05 0.885 0.912 0.926 86 331 279
aFor most variants, showing results for additive model (add). Exception is for trait/variant combination in which one of the genotyping groups has ,5 individuals, for
which the comparison is made between minor allele carriers and non-carriers. Also, showing variants for which the association at p,0.01 is obtained only for minor
allele dominant (dom) or recessive (rec) model.
bcovariates used in analysis: age at baseline, geographic region, cohort, and gender.
cThese variant pairs show similar results due to high LD (r
2.0.96): F5 rs2269648 and rs6029, LCT rs4988235 and rs182549, LCT rs6719488 and rs2236783.
doi:10.1371/journal.pone.0003615.t005
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[31]. Other variants of USF1 have also been reported as showing
significant gender-genotype interaction for triglycerides and BMI
in familial combined hyperlipidemia families [60]. For ischemic
stroke, we identified a variant in F5 as conferring gender-specific
risk, in addition to our previously reported association between
SEPS1 variants and ischemic stroke in women [30]. Importantly,
we identified a larger number of gender-specific effects for women
than for men. For men, only one variant in IL6 gene was
associated with CVD at p#0.01 and interaction p,0.01. The
asymmetry in positive results is similar to a previous large scale
candidate gene study of the metabolic syndrome, in which genetic
effects were stronger in women [27]. This is also consistent with
the larger heritability estimates for stroke and several CVD-related
traits in women [11,13]. These results suggest that genetic effects
on CVD risk may be more readily detectable in women, while for
men the genetic effects are more confounded by environmental/
lifestyle risk factors.
The most consistent result we identified when analyzing women
and men jointly was for a variant in the F12 gene, rs1801020. This
promoter variant is located in the untranslated exon 1 of the gene,
and the T allele was found to be less common in patients with
acute coronary syndrome compared to patients with stable
coronary artery disease [61]. In our study sample, in which the
A (=T) allele was associated with risk of CHD and CVD, the
study setting was very different, and therefore the results are not
readily comparable. Variants in the F12 gene were not present in
the Affymetrix 500K and Illumina 300K chips that have been used
for the recent genome-wide association studies. The strongest
association for quantitative trait variable was between WHR and
an intronic variant of the FUT3 gene, rs11673407. The associated
variant is not one of the four variants previously associated with
Lewis blood phenotype [62] (rs778986 studied here) and which
have been reported to be associated with several CVD-related risk
factors [63].
Two of the genes we selected to this study, LCT and APOBEC2,
have not been previously associated with molecular pathogenesis
of cardiovascular disease. We found association between LCT
variants and both total and LDL cholesterol. Haplotype analysis
implied that the associated variants are in the LCT gene itself, and
not necessarily related to the lactase persistence variant upstream
of the gene. The C allele of the exonic variant rs2304371, which
was associated with highest cholesterol values, is the ancestral
allele, present in other mammals and located in a highly conserved
region. We also found that a variant in APOBEC2 conferred risk of
CHD in men and was associated with higher levels of LDL-C.
APOBEC2 belongs to the cytidine deaminase superfamily, and is
closely related to APOBEC1 [64]. APOBEC1 mediates the editing
of apolipoprotein B mRNA [65]. APOBEC2 is expressed
exclusively in heart and skeletal muscle [64], and its function is
still largely unknown.
To summarize, we have identified several variants of relevant
candidate genes that may confer risk of CHD, ischemic stroke or
CVD and/or associate with quantitative CVD-risk factors in a
gender-specific manner, and other variants which probably confer
risk in both women and men. The identified disease associations
and quantitative trait associations had uncorrected p-values#0.01
for both genders combined and on the basis of the FDR analysis
we expect that half of the findings are true positives. For
interaction analysis, we may expect that at least third of the
reported results are true positives. However, the FDR analysis for
the interaction analysis is conservative, because it does not account
for the additional criteria we used of association p-value,0.01 for
the trait itself in either men or women. Thus, we are convinced
that some of the results represent a real effect of variants on
disease/trait, but obviously require replication in other studies. In
addition, our study had low power to detect genetic effects with
HR,1.8 or coefficient,0.3, thus some of the variants we have
studied that show no genetic effect might represent false negative
results. The possible differences in genetic risk profiles between the
genders should be addressed in more detail in genetic studies of
CVD, and more focus on female CVD risk is warranted also in
genome-wide association studies.
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Table S2 Gender-specific results (p#0.01, uncorrected), in
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Figure S1 Power simulations for time-to-event analysis for risk
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lines connect different value points and are not interpolations.
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Figure S2 Power simulations for quantitative trait analysis using
BMI as an example, testing risk allele frequencies of 0.2 and 0.4,
combining both cohorts, using p-value cut-off of 0.01 and
assuming for interaction analysis (IA) no effect for men while
testing different effect values for women. The lines connect
different value points and are not interpolations. Regression
coefficients are given in standard deviation scale. BMI=body
mass index.
Found at: doi:10.1371/journal.pone.0003615.s006 (7.13 MB TIF)
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